AeroClean’s Pūrgo™ Air Purifier Receives FDA Clearance for the Elimination of SARS-CoV-2
AeroClean Technologies (Nasdaq: AERC) has received FDA 510k clearance for its Pūrgo™ air purifier, allowing it to eliminate SARS-CoV-2, the virus that causes COVID-19. The FDA's review confirmed the device's effectiveness in removing SARS-CoV-2 from indoor air. AeroClean is further testing Pūrgo™ for its efficacy against influenza and respiratory syncytial virus (RSV), amidst a surge in these illnesses. Pūrgo™, classified as a Class II Medical Device, has proven to eliminate 99.99% of harmful airborne microorganisms, including the Omicron variant, with a significant reduction in viral concentration demonstrated in real-world testing.
- FDA 510k clearance granted for Pūrgo™ to eliminate SARS-CoV-2.
- Pūrgo™ demonstrated 99.998% reduction of SARS-CoV-2 in air after 60 minutes.
- Company's ongoing testing for RSV and influenza could enhance market position.
- None.
Additional Testing Being Performed to Confirm Elimination of Influenza and RSV
PALM BEACH GARDENS, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a leading air hygiene technology company, today announced that, the U.S. Food and Drug Administration (“FDA”) has granted AeroClean 510k clearance (K223328) to update its Pūrgo™ air purifier’s (“Pūrgo™”) indications for use to include the elimination of SARS-CoV-2, the RNA virus that causes COVID-19. The FDA has reviewed the laboratory performance data and confirmed the applicability of Pūrgo to remove SARS-CoV-2 from the air in indoor environments. The clearance adds SARS-CoV-2 to the list of microorganisms already cleared. As part of AeroClean’s ongoing commitment to improve Indoor Air Quality (“IAQ”) for a healthier and safer world, the Company has commenced additional efficacy testing on viruses that are known threats to health such as influenza and respiratory syncytial virus (RSV).
“FDA clearance of our Pūrgo™ technology’s ability to eliminate SARs-CoV-2 is an incredible milestone and provides the expected expansion of scope that all of our testing has indicated,” said Jason DiBona, Chief Executive Officer of AeroClean. “Our team is dedicated to improving indoor air quality through the creation of long-term, health-focused solutions, and this latest indication validates the significant strength of our Pūrgo™ air sanitization device. We are currently completing additional testing to determine the efficacy of Pūrgo’s™ ability to remove other airborne microorganisms such as RSV and Influenza. We hope to see the preliminary results shortly.”
Mr. DiBona added, “Its widely known that we are experiencing a ‘tripledemic’, composed of Influenza, RSV, and SARs-CoV-2, that has swept the United States in recent weeks. With the especially high impact these illnesses have had on the public, and particularly the country’s pediatric wards, Pūrgo™ is an essential tool that can be used to help create safer indoor environments.”
AeroClean’s Pūrgo™ air purifier is classified as a Class II Medical Device and utilizes clinical-grade HEPA filtration and germicidal UV-C LED air sanitization technology, proven to eliminate
The independent testing conditions simulated real world environments, with room sized chambers. The independent testing was conducted by Innovative Bioanalysis laboratories to test the efficacy of the AeroClean Pūrgo™ units against SARS-CoV-2, the Omicron variant, during a 60-minute test run. The AeroClean Pūrgo™ unit demonstrated a significant and quantifiable reduction in the recoverable active Omicron variant of SARS-CoV-2 in indoor air space, as shown by a
AeroClean’s efficacy test report on the Omicron Variant of SARS-CoV-2 can be available on request by sending an email to info@aeroclean.com.
For more information about AeroClean technology and Pūrgo™ solutions, visit: www.AeroClean.com.
- Please refer to P-100A IFU document. IFU and previous testing reports are available on request.
About AeroClean Technologies
AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—by improving indoor air quality. Our air hygiene product, Pūrgo™ (pure-go), is an FDA 510(k) cleared, Class II medical device that provides continuous air filtration, sanitization and supplemental ventilation solutions with technology that can be applied in any indoor space - including in hospitals, offices, and even in elevators. Pūrgo™ products feature SteriDuct™, a proprietary germicidal technology developed by our best-in-class aerospace engineers, medical scientists and innovators that work to eradicate viral, fungal, and bacterial airborne microorganisms. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.
Media Contact
Drew Tybus
drew@oakpr.com
Investor Relations Contacts
Ryan Tyler
Chief Financial Officer, AeroClean
RTyler@AeroClean.com
Rob Kelly
MATTIO Communications
aeroclean@mattio.com
FAQ
What is the significance of AeroClean's FDA 510k clearance for AERC?
How effective is the Pūrgo™ air purifier against COVID-19?
What additional testing is AeroClean conducting?
What impact does the 'tripledemic' have on AeroClean Technologies?
What technology does Pūrgo™ use to sanitize air?
